COVID-19 rapid evidence summary: : Sarilumab for COVID-19 [ES34] NICE (published 20th January 2021)

Preliminary evidence from the REMAP ‑CAP study has suggested that sarilumab is beneficial in adults with severe COVID‑19 who are critically ill and receiving respiratory or cardiovascular organ support in an intensive care setting. Sarilumab was given within about 24 hours of starting organ support.It is possible that any benefit from sarilumab is seen only in the most severely ill patients given sarilumab soon after organ support is started, when any developing organ dysfunction may be more reversible.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news